BDY - Bradley Pharmaceuticals, Inc - exceeded estimates in 2 of 3 quarters, with surprises averaging 45%

Bradley has exceeded earnings estimates in two out of the past three quarters, with the positive surprises averaging 45%. One of the two covering analysts raised his estimates for this year. Over the past month, this year's estimates have risen eight cents to 97 cents per share. The stock sports an ROE of 9%, well above the industry average of -4%. Full Analysis Bradley Pharmaceuticals, Inc. (BDY), a pharmaceutical company, engages in acquiring, developing, and marketing prescription and over-the-counter products. It offers various dermatologic and podiatric products, including ADOXA and ZODERM for acne; ROSULA AQUEOUS for rosacea and acne; ROSULA NS PADS for antibacterial treatment; KEROL REDI-CLOTHS and KERALAC for mild to severe dry skin; and KERALAC GEL and KERALAC NAILSTIK for mild to severe dry skin and nail disorders. The company also offers CARMOL for mild to severe dry skin, xerosis, nail disorders, and inflammatory skin conditions; VEREGEN for external genital or perianal warts; SOLARAZE for actinic keratoses and pre-cancerous skin lesions; LIDAMANTLE HC for topical anesthetic and anti-inflammatory; ACIDMANTLE, a cosmetic skin pH balancer; ZONALON for topical anesthetic; SELSEB and CARMOL SCALP LOTION for dandruff; and AFIRM and BETA-LIFT for office procedure for chemical peels. BDY said in mid-March it swung to a fourth-quarter profit, as increased product sales helped it offset competition from some cheaper generics. Quarterly earnings totaled $1.1 million, or 7 cents per share, compared with a prior-year loss of $988,683, or 6 cents per share. The company said the recent quarter included a $3.5 million initial licensing fee, which shaved 13 cents per share off its earnings, and a charge of 4 cents per share related to stock-based compensation costs. Revenue rose to $37.7 million from $30.9 million in the prior-year quarter. President and CEO, Daniel Glassman, stated, "During 2006, Bradley's business strategy evolved to a Commercialize, Develop and In-License model. Bradley's experience in bringing brands to market, expertise in product promotion, knowledge of the niche markets we serve and strong relationships with target physicians makes Bradley well-equipped to successfully commercialize innovative, patent-protected therapies. Bradley's transition to its new business strategy offers Bradley opportunities for portfolio expansion as well as increased sales." Bradley has exceeded earnings estimates in two out of the past three quarters, with the positive surprises averaging 45%. One of the two covering analysts raised his estimates for this year. Over the past month, this year's estimates have risen eight cents to 97 cents per share. The stock sports an ROE of 9%, well above the industry average of -4%. Content Courtesy: Zacks Investment Research #1 Ranked Stocks Highlight Archive To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions. | Blog Home| VitalStocks Home